Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Javier Garcia-Corbacho"'
Autor:
Molly C. Hardebeck, Marie Paule Sablin, Francesco Ricci, Marta Capelán, Marta Puig, Aleix Prat, Mingchi Hsu, Javier Garcia-Corbacho, Anthony Gonçalves, Fadi Braiteh, Douglas Yee, Dennis Chin-Lun Huang, Hiroji Iwata, Patricia LoRusso
Publikováno v:
Cancer Research. 80:CT165-CT165
Introduction: Insulin-like growth factor (IGF) signaling and the cyclin D-cyclin-dependent kinase (CDK) 4 & 6-retinoblastoma pathway are implicated in cancer progression and treatment resistance. Activation of the IGF receptor results in upregulation
Autor:
Richard D. Baird, Simon Pacey, Raj Jena, Duncan I. Jodrell, Stephen J. Price, Nicola Ramenatte, Sarah Jefferies, Carlos Caldas, Michael Williams, Wendi Qian, Javier Garcia-Corbacho, Colin Watts, Saif S Ahmad, Sanjeev Kumar, Tomasz Matys, D. Smith, Andrea Machin, Constanza Linossi
Publikováno v:
Journal of Clinical Oncology. 35:2008-2008
2008 Background: Failure of drugs to cross the blood brain barrier (BBB) can be a major reason for treatment failure in pts with brain tumours. Preliminary data suggest that low-dose RT may disrupt the BBB, and could facilitate increased drug deliver
Autor:
Vincent J. Gnanapragasam, Javier Garcia Corbacho, Elisabeth Oelmann, Sanjeev Kumar, Sara Stearn, Simon Pacey, Richard D. Baird, Ola Bratt, Wanfeng Zhao, Susan Ingle, Nimish Shah, Anne Y. Warren, Mirela Hategan, Elizabeth A. Harrington, Wendi Qian, Barry R. Davies, Leanne K Bell, William Dott
Publikováno v:
Journal of Clinical Oncology. 35:97-97
97 Background: Additional systemic therapy given to unselected patients (pts) around RP has yet to improved pt survival. Further trials should use appropriate pt selection, i.e. men at highest risk of relapse, ideally biomarker stratified. Using nove
Autor:
Sabine C. Linn, Karin Beelen, C Caldas, Richard D. Baird, Cristina Saura, William M. Gallagher, Mariette Schrier, Sudhir Kumar, René Bernards, Hilde Rosing, Constanza Linossi, A. H. M. de Vries Schultink, Anne-Laure Vallier, Iam Mandjes, J. Cortés, Agj van Rossum, Javier Garcia-Corbacho, H. van Tinteren, Susana Muñoz, JM Miquel, Laia Garrigós, J. Tabernero, Marcos Vinicius Silva Oliveira, E. van Werkhoven
Publikováno v:
Cancer Research. 77:OT2-01
Background: The combination of PI3K-AKT-mTOR pathway inhibitors with endocrine therapy can improve clinical outcomes of hormone receptor positive (HR+) metastatic breast cancer (MBC) patients. Taselisib is a potent and selective PI3K inhibitor, with